Don’t miss the latest developments in business and finance.

Jubilant Life Sciences receives final approval for Indomethacin ER Capsule 75mg

Image
Capital Market
Last Updated : Oct 07 2015 | 12:49 PM IST

From USFDA

Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Indomethacin ER Capsule 75mg, which is a non-steriodal anti- inflammatory drug used for treatment of pain.

As on 30 June 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe.

Powered by Capital Market - Live News

More From This Section

First Published: Oct 07 2015 | 11:12 AM IST

Next Story